EMA-HMA Biosimilar Interchangeability Statement Offers ‘Unity And Clarity’ For Europe
Provides Foundation For Uptake Ahead Of Upcoming EU Pharmaceutical Legislation Reform
Executive Summary
The recent statement by the EMA and HMA affirming the interchangeability of biologics and biosimilars has given a boost to Europe’s biosimilars industry ahead of key legislative reforms, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels.
You may also be interested in...
Global Harmonization Efforts Must Go Further
With global regulation of off-patent medicines continuing to evolve, IGBA secretary general Suzette Kox talks about the progress expected from regulatory harmonization for generics and a reduced clinical trial burden for biosimilars.
Global Harmonization Efforts Must Go Further
With global regulation of off-patent medicines continuing to evolve, IGBA secretary general Suzette Kox talks about the progress expected from regulatory harmonization for generics and a reduced clinical trial burden for biosimilars.
Finland Sees Progress On Biosimilar Substitution Plans
Updated plans to implement pharmacy-level biosimilar substitution in Finland have been published by a parliamentary health committee ahead of expected formal approval within weeks, reflecting certain industry criticisms that have now been taken on board.